Remibrutinib

Cat. No.:	HY-128757				
CAS No.:	1787294-07-8				
Molecular Formula:	C ₂₇ H ₂₇ F ₂ N ₅ O ₃				
Molecular Weight:	507.53				
Target:	Btk				
Pathway:	Protein Tyrosine Kinase/RTK				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	2 years		
		-20°C	1 year		


SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (246.29 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	1.9703 mL	9.8516 mL	19.7033 mL		
		5 mM	0.3941 mL	1.9703 mL	3.9407 mL		
		10 mM	0.1970 mL	0.9852 mL	1.9703 mL		
	Please refer to the so	lubility information to select the app	propriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.10 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.10 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.10 mM); Clear solution						

BIOLOGICAL ACTIVITY					
biological Activity					
Description	Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC ₅₀ value of 1 nM. Remibrutinib inhibits BTK activity with an IC ₅₀ value of 0.023 μM in blood ^[1] . Remibrutinib has the potential for Chronic urticaria (CU) treatment ^[2] .				
IC ₅₀ & Target	IC50: 1 nM (BTK) ^[1]				
In Vitro	In a biochemical enzyme assay, Remibrutinib (example 6) inhibits Btk enzymatic activity with an IC ₅₀ value of $1 \text{ nM}^{[1]}$.				

Product Data Sheet





In vitro B cell activation assay, Remibrutinib inhibits Btk enzymatic activity in blood with an IC_{50} value of 0.023 μ M, the whole blood is collected from the abdominal aorta of anaesthetized adult male Lewis rats^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Blood Adv. 2022 Jul 7;bloodadvances.2022007952.
- ACS Pharmacol Transl Sci. 2023 Feb 10.
- Biomed Chromatogr. 2023 Aug 31;e5737.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Daniela Angst, et al. Novel amino pyrimidine derivatives. Patent WO2015079417A1.

[2]. Kolkhir P, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2019 Aug 23.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898Fax: 609-228-5909E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA